NCT02621021 2026-05-08A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of PembrolizumabNational Institutes of Health Clinical Center (CC)Phase 2 Recruiting170 enrolled